HOME >> BIOLOGY >> NEWS
Novel COX-2 combination treatment may reduce colon cancer risk

Philadelphia, PA -- A combination of low-dose COX (cyclooxygenase)-2 inhibitors (celecoxib) and a biologically active component of fish oil (n-3 PUFAs, such as docosahexanoic acid, DHA) may prevent, and even treat, colon cancer, according to data published in the Proceedings for the 94th Annual Meeting of the American Association for Cancer Research (AACR). This effect of the low-dose combination regimen on human colon cancer cells was more pronounced than the use of each agent separately at high doses.

"Any medications taken at high doses may be accompanied by negative side effects, which may make them undesirable for the prevention and treatment of cancer," according to C.V. Rao, Ph.D., Associate Chief, Division of Nutritional Carcinogenesis, Institute For Cancer Prevention, American Health Foundation-Cancer Center, Valhalla, New York. "Therefore, we were pleased to see in our study that the combination treatment of COX-2 and fish oil component (DHA) was effective at tolerable doses."

In the study, human colon cancer cells were treated with several concentrations of celecoxib in combination with DHA, and either celecoxib or DHA alone. The study measured markers including cell growth, cell death, COX-2 expression and activity, and iNOS (inducible nitric oxide synthesis) expression. Results showed that celecoxib and/ or DHA inhibit cell growth and induce cell death at concentrations of >100 M

(micrometer) celecoxib and >150 M DHA in the human colon cancer cell line HCA-7. However, combining low-dose levels of celecoxib (50 M) and DHA (75 M) results in synergistic suppression of cell growth and also induces cell death in HCA-7 cells. Importantly, the key molecular targets of celecoxib and DHA, COX-2 expression and activity, are also synergistically suppressed by low-dose combinations of these agents.

Previous pre-clinical (animal) studies have demonstrated that the administration of fish oil alone reduces the risk of colon cancer by 60 to
'"/>

Contact: Aimee Frank
202-955-6222
American Association for Cancer Research
8-Apr-2003


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2019)... ... February 26, 2019 , ... Circulomics is launching the Short Read ... for long-read sequencing library preparation. , This kit enhances long-read sequencing read lengths ... HMW DNA is not damaged and recovered with high efficiency. Short DNA up to ...
(Date:2/22/2019)... ... February 21, 2019 , ... Clean label food is not ... creating natural foods and beverages. It is quite common to spot consumers running their ... products are not immune to this label scrutiny. , More than ever, meat ...
(Date:2/19/2019)... , ... February 20, 2019 ... ... an agreement that will see Dimensions rolled out across the organization. Dimensions ... data-driven decisions across their business, support strategic planning, and understand past and ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... ... today announced it has begun offering NVIDIA® DGX-1™ deep learning systems as part ... designed to provide the highest performance for artificial intelligence and deep learning research ...
(Date:3/14/2019)... OKLAHOMA CITY (PRWEB) , ... March 14, 2019 ... ... AAALAC International for their facility in Oklahoma City, OK. EyeCRO joins the Department ... University of Oklahoma Health Sciences Center as the fifth institution in Oklahoma to ...
(Date:3/14/2019)... , ... March 14, 2019 , ... ... release announcing that its Canadian partner, the Eye Machine Canada Inc., had been ... Oculus’s pioneering technology for treating Age-Related Macular Degeneration (AMD). , The previous month, ...
(Date:3/14/2019)... LAWRENCEVILLE, N.J. (PRWEB) , ... ... ... announced the launch of a preclinical gold standard solution for preclinical research ... Execution System (LES) with end-to-end workflows, connected systems and facilities, innovative technology-driven ...
Breaking Biology Technology:
Cached News: